Stockreport

Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]

Atea Pharmaceuticals, Inc. - common stock  (AVIR) 
PDF Topline Results from North American Phase 3 C-BEYOND Trial Expected Mid-2026; Results from C-FORWARD Trial Outside North America Expected Year-End 2026 C-BEYOND and C [Read more]